Acorda Therapeutics (ACOR) Tops Q2 EPS by 48c, Revenues Beat; Offers FY19 Sales Guidance
Tweet Send to a Friend
Acorda Therapeutics (NASDAQ: ACOR) reported Q2 EPS of ($0.58), $0.48 better than the analyst estimate of ($1.06). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
